Development of a Series of Tanshinone Derivatives Through Scaffold Hopping for Treating Non-Small-Cell Lung Cancer...

Area of Science:

• Medicinal Chemistry
• Oncology
• Drug Discovery

Background:

• Non-small-cell lung cancer (NSCLC) is a leading cause of cancer mortality worldwide.
• Tanshinone derivatives possess known antitumor properties, making them candidates for further investigation.
• Developing novel, potent, and safe anti-NSCLC agents remains a critical unmet medical need.

Purpose of the Study:

• To design and synthesize novel tanshinone derivatives using a scaffold-hopping strategy.
• To evaluate the cytotoxic and antiproliferative activities of these derivatives against NSCLC cell lines.
• To assess the safety profile of the synthesized compounds in normal lung cells.

Main Methods:

• Synthesis of 35 novel tanshinone derivatives.
• In vitro cytotoxicity assays using A549 and H838 NSCLC cell lines.
• Safety assessment in BEAS-2B normal lung cells.
• Molecular docking studies (S2-4/NLRP3, S2-14/STAT3) and structure-activity relationship (SAR) analysis.

Main Results:

• Compounds S2-1, S2-4, and S2-8 demonstrated superior inhibition against A549 cells compared to the positive control.
• Compounds S2-1, S2-3, S2-4, S2-8, S2-13, and S2-14 showed significant antiproliferation activity against H838 cells.
• S2-4 (0.58 μM) and S2-8 (0.42 μM) exhibited the highest potency against H838 cells; S2-13 and S2-14 showed potent and selective activity.

Conclusions:

• The synthesized tanshinone derivatives exhibit promising anti-NSCLC activity.
• Specific derivatives, notably S2-4 and S2-8, show significant potency and selectivity.
• The benzofuran core with an ortho-quinone, amide linkage, and triazole group is identified as a key structural motif for enhanced anti-NSCLC efficacy.